10 research outputs found

    Using multi-criteria decision analysis (MCDA) to support health research funding decision-making

    Get PDF
    There is a growing body of literature using multi-criteria decision analysis (MCDA) methods for prioritising health interventions. However, there has been very little application of MCDA to prioritise funding for research across health conditions, including non-communicable diseases (NCDs). NCDs are non-transmissible diseases that are not spread from person to person – e.g. diabetes mellitus, coronary heart disease, back pain, dementia and depression. Given limited resources, funding needs to be systematically allocated for research into the most pressing NCDs by explicitly identifying priorities for health research. Methods based on MCDA have attracted increasing attention by policy-makers and researchers by systematically forming and solving the multi-dimensional aspects of the decision problems, particularly in the health system. This thesis aims to investigate the use of MCDA to support health research funding across NCDs. Following chapters of introduction and a review of commonly used methods, the thesis includes three main chapters (i.e. Chapters 3, 4 and 5), as well as the concluding chapter that provides policy implications and research contributions of the thesis. In Chapter 3, a widely-used MCDA method – i.e. the Potentially All Pairwise RanKings of all possible Alternatives (PAPRIKA) method administered through 1000minds software – is applied to create a priority list of NCDs to support health research funding. Informed by the literature, a set of prioritisation criteria – e.g. deaths, loss of quality-of-life and cost of the disease – is specified to evaluate NCDs in terms of their priority for health research funding decision-making. Their weights, representing their relative importance, are calculated based on a survey of stakeholders from various sectors of the New Zealand (NZ) health system. The most important criterion for prioritising NCDs in terms of their overall burden to society (and hence their importance for health research funding) is ‘deaths across the population’ (mean weight = 27.7%), followed by ‘loss of quality-of-life across the population’ (23.0%), then ‘cost of the disease to patients and families’ (18.6%), ‘cost of the disease to the health system’ (17.2%) and the least-important criterion, ‘disproportionately affects vulnerable groups’ (13.4%). The criteria are used to rate NCDs based on evidence concerning their performance on the criteria. The rated NCDs are then ranked using the criteria mean weights from the survey. Each NCD’s total score is presented based on a 0-100% scale, where 100% indicated an NCD with the highest levels on all criteria, and 0%, an NCD with the lowest levels on all criteria. The NCDs ranking is categorised into four tiers: Priority 1 (very critical): coronary heart disease, back and neck pain, diabetes mellitus; Priority 2 (critical): dementia and Alzheimer’s disease, stroke; Priority 3 (high): colon and rectum cancer, depressive disorders, chronic obstructive pulmonary disease, chronic kidney disease, breast cancer, prostate cancer, arthritis, lung cancer; Priority 4 (medium): asthma, hearing loss, melanoma skin cancer, addictive disorders, non-melanoma skin cancer, headaches. The MCDA-based framework developed in Chapter 3 enables incorporating multiple criteria for evaluating a range of NCDs in terms of their priority for research funding and the involvement of a diverse range of stakeholders. This framework is hence more likely to generate a priority list that is more acceptable to the key stakeholders. This priority list shows that it is essential to incorporate the multi-dimensional nature – e.g. mortality, morbidity and health care costs – of NCDs when evaluating their priority and eligibility for health research funding. In Chapter 4, PAPRIKA is compared with the most well known and thus, the most widely-used MCDA method – i.e. the Analytic Hierarchy Process (AHP) administered using Expert Choice software. AHP is considered as a benchmark among the MCDA methods by many MCDA practitioners. Both AHP and PAPRIKA are two prominent MCDA methods that have been used in many different fields and appeared in many publications. It is worthwhile to compare the two methods based on their theoretical foundations. Along with AHP and PAPRIKA, their associated decision-making software – i.e. Expert Choice and 1000minds – are considered in the evaluation framework. The findings indicate that AHP (and Expert Choice) and PAPRIKA (and 1000minds) use different theoretical foundations at different stages of the decision-making process from eliciting participants’ preferences to calculating the criteria weights and alternatives scores. As such, PAPRIKA uses choice-based pairwise comparison questions, whereas AHP uses ratio scale-based paired comparison questions to elicit participants’ preferences. AHP, unlike PAPRIKA, does not enforce the transitivity property. In Chapter 5, an empirical framework is established to evaluate the performance of AHP (and Expert Choice) and PAPRIKA (and 1000minds) based on the NCD survey (the main subject of this thesis), as well as a second survey about smartphones. In the framework, a holdout choice task is employed for investigating the performance of AHP (and Expert Choice) and PAPRIKA (and 1000minds) to predict participants’ actual choices. The findings reveal that PAPRIKA (and 1000minds) is more likely to outperform AHP (and Expert Choice) based on both decision case studies about NCDs and smartphones. PAPRIKA could produce repeatable results over time and show higher validity to predict participants’ actual choices. Given the diversity of MCDA methods and in the absence of a gold standard, evaluating the chosen MCDA method(s) based on their theoretical foundations may not be sufficient. An appropriate MCDA method is also required to produce robust results. Ideally, the theoretical and empirical frameworks developed in Chapters 4 and 5 could help MCDA practitioners consider a holistic approach to justify the choice of MCDA – which is the primary purpose of ‘step 7’ in the MCDA process – and choose a method that is developed on sound theoretical foundations and that generates robust results

    External validity of multi-criteria preference data obtained from non-random sampling: measuring cohesiveness within and between groups

    No full text
    An important component of multi-criteria decision analysis (MCDA) in the public sector is the elicitation and aggregation of preferences data collected via surveys into the relative importance of the criteria for the decision at hand. These aggregated preferences data, usually in the form of mean weights on the criteria, are intended to represent the preferences of the relevant population overall. However, random sampling is often not feasible for public-sector MCDA for logistical reasons, including the expense involved in identifying and recruiting participants. Instead, non-random sampling methods such as convenience, purposive or snowball sampling are widely used. Nonetheless, provided the preferences data collected are sufficiently ‘cohesive’ in terms of the extent to which the weights of the individuals belonging to the various exogenously defined groups in the sample are similar, non-random sampling can still produce externally valid aggregate preferences data. We explain a method for measuring cohesiveness using the Kemeny and Hellinger distance measures, which involve measuring the ‘distance’ of participants’ weights (and the corresponding rankings of the criteria) from each other, within and between the groups respectively. As an illustration, these distance measures are applied to data from a MCDA to rank non-communicable diseases according to their overall burden to society. We conclude that the method is useful for evaluating the external validity of preferences data obtained from non-random sampling

    Scoping literature review of evidence on cost and effectiveness outcomes of non-medical prescribing by health professionals

    No full text
    Protocol for a scoping literature review study to identify and map the evidence on cost and effectiveness outcomes of non-medical prescribing by health professional

    Costs, consequences and value for money in non-medical prescribing: a scoping review

    Get PDF
    Objectives Non-medical prescribing (NMP) is a key feature of the UK healthcare system that refers to the legal prescribing rights granted to nurses, pharmacists and other non-medical healthcare professionals who have completed an approved training programme. NMP is deemed to facilitate better patient care and timely access to medicine. The aim of this scoping review is to identify, synthesise and report the evidence on the costs, consequences and value for money of NMP provided by non-medical healthcare professionals. Design: Scoping review Data sources: MEDLINE, Cochrane Library, Scopus, PubMed, ISI Web of Science and Google Scholarwere systematically searched from 1999 to 2021. Eligibility criteria: Peer-reviewed and grey literature written in English were included. The research was limited to original studies evaluating economic values only or both consequences and costs of NMP. Data extraction and synthesis: The identified studies were screened independently by two reviewers for final inclusion. The results were reported in tabular form and descriptively. Results: A total of 420 records were identified. Of these, nine studies evaluating and comparing NMP with patient group discussions, GP-led usual care, or services provided by non-prescribing colleagues were included. All studies evaluated the costs and economic values of prescribing services by nonmedical prescribers, and eight assessed patient, health or clinical outcomes. Three studies showed pharmacist prescribing was superior in all outcomes and cost-saving at large scale. Others reported similar results in most health and patient outcomes across other non-medical prescribers and control groups. NMP was deemed resource-intensive to both providers and other groups of non-medical prescribers (e.g. nurses, physiotherapists, podiatrists). Conclusions: The review demonstrated the need for quality evidence from more rigorous methodological studies examining all relevant costs and consequences to show value for money in NMP and inform the commissioning of NMP for different groups of healthcare professionals
    corecore